Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 3 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sphingotec GmbH is currently facing 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 3 distinct examiners, which indicates that some examiners are reviewing multiple applications within the portfolio. This concentration of work can lead to more consistent outcomes if the examiner's feedback is applied across related cases. The portfolio is also active in 3 distinct art units, suggesting a focused technical scope within the biotechnology sector.
SAOUD, CHRISTINE J. is the busiest examiner for this company, with 4 busiest examiner pending actions currently on her docket. Given the total of 6 pending office actions, this single examiner is responsible for a significant majority of the company's active cases. This high level of concentration with SAOUD, CHRISTINE J. allows the applicant to focus their primary prosecution efforts on a single individual's requirements. The remaining actions are distributed among the other 3 distinct examiners across the 3 distinct art units, providing a secondary focus for the company's legal strategy.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAOUD, CHRISTINE J | 3 | 57.9% | +37.5% |
| BOWLES, DAVID PAUL | 1 | 69.6% | +28.1% |
| MARCSISIN, ELLEN JEAN | 1 | 34.6% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16781226 | ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE | SAOUD, CHRISTINE J | 37d overdue |
| 18568334 | A METHOD FOR PREDICTING SEPSIS AND SEPTIC SHOCK | BOWLES, DAVID PAUL | — |
| 17955765 | METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT | MARCSISIN, ELLEN JEAN | — |
| 16968483 | SAMPLE OF BODILY FLUID AND A BINDER TO MATURE ADM-NH2 | SAOUD, CHRISTINE J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18148633 | TREATMENT OF DEMENTIA OR ALZHEIMER'S AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADRENOMEDULLIN ANTIBODY FRAGMENT | SAOUD, CHRISTINE J | 88d overdue |
| 16781226 | ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE | SAOUD, CHRISTINE J | 37d overdue |
| 18568334 | A METHOD FOR PREDICTING SEPSIS AND SEPTIC SHOCK | BOWLES, DAVID PAUL | — |
| 17955765 | METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT | MARCSISIN, ELLEN JEAN | — |
| 16968483 | SAMPLE OF BODILY FLUID AND A BINDER TO MATURE ADM-NH2 | SAOUD, CHRISTINE J | — |
| Art Unit | Apps |
|---|---|
| 1645 | 3 |
| 1654 | 1 |
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18568334 | A METHOD FOR PREDICTING SEPSIS AND SEPTIC SHOCK | BOWLES, DAVID PAUL | 1654 | §102§112 | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18148633 | TREATMENT OF DEMENTIA OR ALZHEIMER'S AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADRENOMEDULLIN ANTIBODY FRAGMENT | SAOUD, CHRISTINE J | 1645 | §112 | Final Rejection | 88d overdue | Pending | Dec 30, 2022 |
| 17955765 | METHOD FOR PREDICTING THE RISK OF GETTING CANCER OR DIAGNOSING CANCER IN A FEMALE SUBJECT | MARCSISIN, ELLEN JEAN | 1677 | §101§112DP | Final Rejection | — | Pending | Sep 29, 2022 |
| 16968483 | SAMPLE OF BODILY FLUID AND A BINDER TO MATURE ADM-NH2 | SAOUD, CHRISTINE J | 1645 | §102§112 | Non-Final OA | — | Pending | Aug 07, 2020 |
| 16781226 | ADRENOMEDULLIN TO GUIDE THERAPY OF BLOOD PRESSURE DECLINE | SAOUD, CHRISTINE J | 1645 | §102§112 | Non-Final OA | 37d overdue | Pending | Feb 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSphingotec GmbH has 5 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Christine J Saoud has the most, with 3 of Sphingotec GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
